CAAS Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

CAAS Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,824	Closed	-$210K	–	1024
2022 Q2	$210K	Buy	+2,824	New	+$212K	0.01%	656

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

CAAS Capital Management's XBI Position: Q3 2022 in Review

CAAS Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2022, closing a stake of 2,824 shares — an estimated $210K sold.

CAAS Capital Management first reported a position in XBI in Q2 2022 and held it in 1 quarter. The position peaked at $210K in Q2 2022. 704 funds tracked by Wall St. Rank hold XBI as of Q3 2022.

CAAS Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2022 after selling out during the quarter.
CAAS Capital Management sold 2,824 State Street SPDR S&P Biotech ETF shares in Q3 2022, an estimated $210K.
CAAS Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and held it in 1 quarter.
CAAS Capital Management's State Street SPDR S&P Biotech ETF position peaked at $210K in Q2 2022.
704 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2022.

Based on CAAS Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.